tetano
Editor, Senior Moderator
PLoS One
. 2020 Dec 31;15(12):e0244628.
doi: 10.1371/journal.pone.0244628. eCollection 2020.
Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis
Julie Gorham[SUP] 1 [/SUP], Anthony Moreau[SUP] 1 [/SUP], Francis Corazza[SUP] 2 [/SUP], Lorenzo Peluso[SUP] 1 [/SUP], Fanny Ponthieux[SUP] 2 [/SUP], Marta Talamonti[SUP] 1 [/SUP], Antonio Izzi[SUP] 1 [/SUP], Carole Nagant[SUP] 2 [/SUP], Narcisse Ndieugnou Djangang[SUP] 1 [/SUP], Alessandra Garufi[SUP] 1 [/SUP], Jacques Creteur[SUP] 1 [/SUP], Fabio Silvio Taccone[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) appeared in China in December 2019 and has spread around the world. High Interleukin-6 (IL-6) levels in COVID-19 patients suggest that a cytokine storm may play a major role in the pathophysiology and are considered as a relevant parameter in predicting most severe course of disease. The aim of this study was to assess repeated IL-6 levels in critically ill COVID-19 patients admitted to our Intensive Care Unit (ICU) and to evaluate their relationship with patient's severity and outcome.
Methods: We conducted a retrospective study on patients admitted to the ICU with a diagnosis of COVID-19 between March 10 (i.e. the date of the first admitted patients) and April 30, 2020. Demographic, clinical and laboratory data were collected at admission. On the day of IL-6 blood concentration measurement, we also collected results of D-Dimers, C-Reactive Protein, white blood cells and lymphocytes count, lactate dehydrogenase (LDH) and ferritin as well as microbiological samples, whenever present.
Results: Of a total of 65 patients with COVID-19 admitted to our ICU we included 41 patients with repeated measure of IL-6. There was a significant difference in IL-6 levels between survivors and non-survivors over time (p = 0.001); moreover, non survivors had a significantly higher IL-6 maximal value when compared to survivors (720 [349-2116] vs. 336 [195-646] pg/mL, p = 0.01). The IL-6 maximal value had a significant predictive value of ICU mortality (AUROC 0.73 [95% CI 0.57-0.89]; p = 0.01).
Conclusions: Repeated measurements of IL-6 can help clinicians in identifying critically ill COVID-19 patients with the highest risk of poor prognosis.
. 2020 Dec 31;15(12):e0244628.
doi: 10.1371/journal.pone.0244628. eCollection 2020.
Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis
Julie Gorham[SUP] 1 [/SUP], Anthony Moreau[SUP] 1 [/SUP], Francis Corazza[SUP] 2 [/SUP], Lorenzo Peluso[SUP] 1 [/SUP], Fanny Ponthieux[SUP] 2 [/SUP], Marta Talamonti[SUP] 1 [/SUP], Antonio Izzi[SUP] 1 [/SUP], Carole Nagant[SUP] 2 [/SUP], Narcisse Ndieugnou Djangang[SUP] 1 [/SUP], Alessandra Garufi[SUP] 1 [/SUP], Jacques Creteur[SUP] 1 [/SUP], Fabio Silvio Taccone[SUP] 1 [/SUP]
Affiliations
- PMID: 33382773
- DOI: 10.1371/journal.pone.0244628
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) appeared in China in December 2019 and has spread around the world. High Interleukin-6 (IL-6) levels in COVID-19 patients suggest that a cytokine storm may play a major role in the pathophysiology and are considered as a relevant parameter in predicting most severe course of disease. The aim of this study was to assess repeated IL-6 levels in critically ill COVID-19 patients admitted to our Intensive Care Unit (ICU) and to evaluate their relationship with patient's severity and outcome.
Methods: We conducted a retrospective study on patients admitted to the ICU with a diagnosis of COVID-19 between March 10 (i.e. the date of the first admitted patients) and April 30, 2020. Demographic, clinical and laboratory data were collected at admission. On the day of IL-6 blood concentration measurement, we also collected results of D-Dimers, C-Reactive Protein, white blood cells and lymphocytes count, lactate dehydrogenase (LDH) and ferritin as well as microbiological samples, whenever present.
Results: Of a total of 65 patients with COVID-19 admitted to our ICU we included 41 patients with repeated measure of IL-6. There was a significant difference in IL-6 levels between survivors and non-survivors over time (p = 0.001); moreover, non survivors had a significantly higher IL-6 maximal value when compared to survivors (720 [349-2116] vs. 336 [195-646] pg/mL, p = 0.01). The IL-6 maximal value had a significant predictive value of ICU mortality (AUROC 0.73 [95% CI 0.57-0.89]; p = 0.01).
Conclusions: Repeated measurements of IL-6 can help clinicians in identifying critically ill COVID-19 patients with the highest risk of poor prognosis.